Skip to main content

Table 2 The responses to the Moxifloxacin or placebo creams in the groups

From: Efficacy of topical moxifloxacin on therapeutic laparoscopy-induced wound healing: a double-blind, randomized clinical trial

day

Baseline

First day

Third day

Fifth day

Redness

R’

R’’

R’’’

R’’’’

R’

R’’

R’’’

R’’’’

R’

R’’

R’’’

R’’’’

R’

R’’

R’’’

R’’’’

MXF

2 (5.0)

5 (12.5)

12 (30.0)

21 (52.5)

16 (40.0)

18 (45.0)

5 (12.5)

1 (2.5)

32 (80.0)

4 (10.0)

3 (7.5)

1 (2.5)

36 (90.0)

2 (5.0)

1 (2.5)

1 (2.5)

Placebo

3 (7.5)

3 (7.5)

10 (25)

24 (60)

3 (7.5)

1 (2.5)

13 (32.5)

23 (57.5)

7 (17.5)

8 (20.0)

10 (25.0)

15 (37.5)

14 (35.0)

7 (17.5)

9 (22.5)

9 (22.5)

P-Value

0.558

< 0.0001

< 0.0001

< 0.0001

Oedema

O’

O’’

O’’’

O’’’’

O’

O’’

O’’’

O’’’’

O’

O’’

O’’’

O’’’’

O’

O’’

O’’’

O’’’’

MXF

14 (35.0)

12 (30.0)

9 (22.5)

5 (12.5)

27 (67.5)

8 (20.0)

2 (5.0)

3 (7.5)

33 (82.5)

0 (0.0)

1 (2.5)

1 (2.5)

35 (87.5)

4 (10)

0 (0.0)

1 (2.5)

placebo

14 (35.0)

9 (22.5)

9 (22.5)

8 (20.0)

18 (45.0)

7 (17.5)

9 (22.5)

6 (15.0)

23 (57.5)

5 (12.5)

3 (7.5)

3 (7.5)

25 (62.5)

8 (20)

5 (12.5)

2 (5.0)

P-Value

0.559

0.022

0.010

0.008

Ecchymosis

E’

E’’

E’’’

E’’’’

E’

E’’

E’’’

E’’’’

E’

E’’

E’’’

E’’’’

E’

E’’

E’’’

E’’’’

MXF

16 (40.0)

13 (32.5)

7 (17.5)

4 (10)

22 (55.0)

11 (27.5)

4 (10.0)

3 (7.5)

32 (80.0)

6 (15.0)

2 (5.0)

0 (0.0)

32 (80)

7 (17.5)

1 (2.5)

0 (0.0)

placebo

17 (42.5)

6 (15.0)

6 (15.0)

11 (27.5)

17 (42.5)

7 (17.5)

5 (12.5)

11 (27.5)

20 (50.0)

4 (10.0)

10 (25.0)

6 (15.0)

23 (57.5)

6 (15.0)

6 (15.0)

5 (12.5)

P-Value

0.396

0.066

0.001

0.01

Discharge

D’

D’’

D’’’

D’’’’

D’

D’’

D’’’

D’’’’

D’

D’’

D’’’

D’’’’

D’

D’’

D’’’

D’’’’

MXF

4 (10.0)

10 (25.0)

9 (22.5)

17 (42.5)

25 (62.5)

11 (27.5)

3 (7.5)

1 (2.5)

31 (77.5)

8 (20.0)

0 (0.0)

1 (2.5)

32 (80.0)

7 (17.5)

0 (0.0)

1 (2.5)

placebo

0 (0.0)

13 (32.5)

9 (22.5)

18 (45.0)

2 (5.0)

16 (40.0)

8 (20.0)

14 (35.0)

9 (22.5)

14 (35.0)

10 (25.0)

7 (17.5)

16 (40.0)

12 (30.0)

5 (12.5)

7 (17.5)

P-Value

0.605

< 0.0001

< 0.0001

< 0.0001

Approximation

A’

A’’

A’’’

A’’’’

A’

A’’

A’’’

A’’’’

A’

A’’

A’’’

A’’’’

A’

A’’

A’’’

A’’’’

MXF

0 (0.0)

29 (72.5)

11 (27.5)

0 (0.0)

3 (7.5)

29 (72.5)

8 (20.0)

0 (0.0)

20 (50.0)

16 (40.0)

4 (10.0)

0 (0.0)

27 (67.5)

11 (27.5)

2 (5.0)

0 (0.0)

placebo

0 (0.0)

26 (65)

13 (32.5)

1 (2.5)

1 (2.5)

27 (67.5)

12 (30.0)

0 (0.0)

13 (32.5)

21 (52.5)

6 (15.0)

0 (0.0)

22 (55.0)

16 (40.0)

2 (5.0)

0 (0.0)

P-Value

0.434

0.203

0.123

0.285

REEDA

MXF

7.65 ± 2.58

3.65 ± 2.35

1.7 ± 1.3

1.18 ± 1.06

placebo

8.38 ± 2.86

7.8 ± 2.83

5.8 ± 2.9

4.35 ± 2.98

P-Value

0.209

< 0.0001

< 0.0001

< 0.0001

  1. Data is based on frequency (%) and mean ± SD
  2. R’: 0 = none, R’’: 1 = mild within 0.25 cm of incision, R’’’:2 = moderate within 0.5 cm of incision bilaterally, R’’’’: 3 = severe beyond 0.5 cm of incision bilaterally
  3. O’: 0 = none, O’’:1 = mild perineal, less than 1 cm from the incision, O’’’:2 = moderate perineal and\or vulvar, between 1 and 2 cm from the incision, O’’’’:3 = severe perineal and\or vulvar, greater than 2 cm from an incision
  4. E’: 0 = none, E’’:1 = mild within 0.25 cm bilaterally or 0.5 cm unilaterally, E’’’: 2 = moderate between 0.25 and 1 cm bilaterally or between 0.5 and 2 cm unilaterally, E’’’’:3 = severe greater than 1 cm bilaterally or 2 cm unilaterally
  5. D’:0 = none, D’’:1 = serous, D’’’:2 = serosanguinous, D’’’’:3 = bloody, purulent
  6. A’: 0 = closed, A’’:1 = mild skin separation of 3 mm or less, A’’’:2 = moderate skin and subcutaneous fat separation, A’’’’: 3 = severe skin and subcutaneous fat and fascial layer separation
Back to article page

BMC Surgery

ISSN: 1471-2482

Contact us